Format

Send to

Choose Destination
Anticancer Res. 2017 Dec;37(12):6879-6886.

Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.

Author information

1
Service de Chirurgie Oncologique et Gynécologique - Obstétrique, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France.
2
EMR UCBL/HCL 3738, Faculté De Médecine Lyon Sud, Université Lyon 1, Oullins, France.
3
Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, CITOHL, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France.
4
EMR UCBL/HCL 3738, Faculté De Médecine Lyon Sud, Université Lyon 1, Oullins, France benoit.you@chu-lyon.fr.

Abstract

AIM:

To investigate the prognostic value of modeled CA-125 kinetic parameters regarding surgery outcomes and time to second-line chemotherapy in a population of ovarian cancer patients treated with neoadjuvant chemotherapy followed by interval cytoreduction.

PATIENTS AND METHODS:

This retrospective study included consecutive patients with FIGO stage IIIc/IV ovarian cancer treated between 2006 and 2014. We characterized CA-125 kinetics and identified modeled kinetic parameters.

RESULTS:

Fifty four patients were included. KELIM (modeled CA-125 elimination rate constant) was an independent predictive parameter of optimal cytoreduction (OR=0.18; 95% CI=0.04-0.69; p=0.02). In the optimal cytoreduction population (40 patients, 74.1%), E50 (concentration producing 50% of the maximum chemotherapy effect) was a significant prognostic parameter regarding time to second-line chemotherapy (HR=0.38; 95% CI=0.173-0.854; p=0.019).

CONCLUSION:

We identified CA-125 modeled kinetic parameters during neoadjuvant chemotherapy harboring potential predictive values regarding the likelihood of optimal cytoreduction, along with time to second-line chemotherapy in optimally-cytoreduced patients.

KEYWORDS:

CA-125 kinetics; Epithelial ovarian cancer; cytoreduction prediction; mathematical modeling; neoadjuvant chemotherapy; second-line chemotherapy

PMID:
29187468
DOI:
10.21873/anticanres.12150
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center